Annual CFF
$31.30 M
-$22.01 M-41.28%
December 31, 2023
Summary
- As of February 7, 2025, SLN annual cash flow from financing activities is $31.30 million, with the most recent change of -$22.01 million (-41.28%) on December 31, 2023.
- During the last 3 years, SLN annual CFF has risen by +$11.50 million (+58.08%).
- SLN annual CFF is now -47.69% below its all-time high of $59.83 million, reached on December 31, 2015.
Performance
SLN Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$11.97 M
+$11.61 M+3214.70%
September 1, 2024
Summary
- As of February 7, 2025, SLN quarterly cash flow from financing activities is $11.97 million, with the most recent change of +$11.61 million (+3214.70%) on September 1, 2024.
- Over the past year, SLN quarterly CFF has dropped by -$36.80 thousand (-0.31%).
- SLN quarterly CFF is now -91.06% below its all-time high of $133.90 million, reached on March 31, 2024.
Performance
SLN Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$158.24 M
-$3.31 M-2.05%
September 1, 2024
Summary
- As of February 7, 2025, SLN TTM cash flow from financing activities is $158.24 million, with the most recent change of -$3.31 million (-2.05%) on September 1, 2024.
- Over the past year, SLN TTM CFF has increased by +$126.94 million (+405.54%).
- SLN TTM CFF is now -4.20% below its all-time high of $165.17 million, reached on March 31, 2024.
Performance
SLN TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
SLN Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -41.3% | -0.3% | +405.5% |
| 3 y3 years | +58.1% | +344.2% | +196.8% |
| 5 y5 years | +6779.3% | +344.2% | +196.8% |
SLN Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -41.3% | at low | -91.1% | >+9999.0% | -4.2% | >+9999.0% |
| 5 y | 5-year | -41.3% | +364.9% | -91.1% | >+9999.0% | -4.2% | >+9999.0% |
| alltime | all time | -47.7% | >+9999.0% | -91.1% | >+9999.0% | -4.2% | >+9999.0% |
Silence Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $11.97 M(+3214.7%) | $158.24 M(-2.0%) |
| Jun 2024 | - | $361.20 K(-99.7%) | $161.55 M(-2.2%) |
| Mar 2024 | - | $133.90 M(+1014.9%) | $165.17 M(+427.7%) |
| Dec 2023 | $31.30 M(-41.3%) | $12.01 M(-21.4%) | $31.30 M(+42.4%) |
| Sep 2023 | - | $15.28 M(+283.4%) | $21.99 M(-61.7%) |
| Jun 2023 | - | $3.99 M(>+9900.0%) | $57.39 M(+7.5%) |
| Mar 2023 | - | $23.10 K(-99.1%) | $53.40 M(+0.2%) |
| Dec 2022 | $53.31 M(+26.2%) | $2.70 M(-94.7%) | $53.31 M(+5.5%) |
| Sep 2022 | - | $50.69 M(<-9900.0%) | $50.52 M(<-9900.0%) |
| Jun 2022 | - | -$9900.00(-84.3%) | -$155.30 K(-144.0%) |
| Mar 2022 | - | -$63.10 K(-32.4%) | $352.60 K(-99.2%) |
| Dec 2021 | $42.25 M(+113.4%) | -$93.30 K(-948.2%) | $42.25 M(-0.2%) |
| Sep 2021 | - | $11.00 K(-97.8%) | $42.34 M(+0.0%) |
| Jun 2021 | - | $498.00 K(-98.8%) | $42.33 M(+1.2%) |
| Mar 2021 | - | $41.83 M | $41.83 M |
| Dec 2020 | $19.80 M(+194.1%) | - | - |
| Dec 2019 | $6.73 M(+1379.8%) | - | - |
| Dec 2018 | $455.00 K(+633.9%) | - | - |
| Dec 2017 | $62.00 K(-145.3%) | - | - |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2016 | -$136.80 K(-100.2%) | - | - |
| Dec 2015 | $59.83 M(+234.7%) | - | - |
| Dec 2014 | $17.88 M(-39.2%) | - | - |
| Dec 2013 | $29.39 M(+81.0%) | - | - |
| Dec 2012 | $16.24 M(+83.5%) | - | - |
| Dec 2011 | $8.85 M(-53.8%) | - | - |
| Dec 2010 | $19.14 M(+358.4%) | - | - |
| Dec 2009 | $4.18 M(>+9900.0%) | - | - |
| Dec 2008 | $5500.00(-99.9%) | - | - |
| Dec 2007 | $10.35 M(+58.3%) | - | - |
| Dec 2006 | $6.54 M(-62.0%) | - | - |
| Dec 2005 | $17.20 M(>+9900.0%) | - | - |
| Dec 2004 | $9200.00(-99.8%) | - | - |
| Dec 2000 | $5.87 M(-54.7%) | - | - |
| Dec 1999 | $12.95 M(+2603.8%) | - | - |
| Dec 1998 | $479.00 K(+4787.8%) | - | - |
| Dec 1997 | $9800.00(-99.9%) | - | - |
| Dec 1996 | $9.80 M(+280.6%) | - | - |
| Dec 1995 | $2.57 M | - | - |
FAQ
- What is Silence Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Silence Therapeutics?
- What is Silence Therapeutics annual CFF year-on-year change?
- What is Silence Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Silence Therapeutics?
- What is Silence Therapeutics quarterly CFF year-on-year change?
- What is Silence Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Silence Therapeutics?
- What is Silence Therapeutics TTM CFF year-on-year change?
What is Silence Therapeutics annual cash flow from financing activities?
The current annual CFF of SLN is $31.30 M
What is the all time high annual CFF for Silence Therapeutics?
Silence Therapeutics all-time high annual cash flow from financing activities is $59.83 M
What is Silence Therapeutics annual CFF year-on-year change?
Over the past year, SLN annual cash flow from financing activities has changed by -$22.01 M (-41.28%)
What is Silence Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of SLN is $11.97 M
What is the all time high quarterly CFF for Silence Therapeutics?
Silence Therapeutics all-time high quarterly cash flow from financing activities is $133.90 M
What is Silence Therapeutics quarterly CFF year-on-year change?
Over the past year, SLN quarterly cash flow from financing activities has changed by -$36.80 K (-0.31%)
What is Silence Therapeutics TTM cash flow from financing activities?
The current TTM CFF of SLN is $158.24 M
What is the all time high TTM CFF for Silence Therapeutics?
Silence Therapeutics all-time high TTM cash flow from financing activities is $165.17 M
What is Silence Therapeutics TTM CFF year-on-year change?
Over the past year, SLN TTM cash flow from financing activities has changed by +$126.94 M (+405.54%)